Cardiff Oncology (CRDF) Capital Expenditures (2011 - 2025)

Cardiff Oncology has reported Capital Expenditures for 15 years, with the latest figure at $18000.0 in Q3 2025.

• Quarterly Capital Expenditures changed N/A year-over-year to $18000.0 in Q3 2025, while the trailing twelve-month figure through Dec 2025 was $44000.0 (down 45.0% YoY) and the FY2025 annual result came in at $44000.0, down 45.0% from the prior year.
• Capital Expenditures improved to $18000.0 in Q3 2025 per CRDF's latest filing, from -$876000.0 in the prior quarter.
• Over five years, Capital Expenditures peaked at $902000.0 in Q1 2025 and troughed at -$876000.0 in Q2 2025.
• A 5-year average of $72615.4 and a median of $126000.0 in 2023 frame the typical range for Capital Expenditures.
• The sharpest annual moves came in 2022 and 2025: Capital Expenditures plunged 11750.0% in 2022, then soared 1027.5% in 2025.
• Over 5 years, Capital Expenditures stood at $6000.0 in 2021, then slumped by 11750.0% to -$699000.0 in 2022, then surged by 101.14% to $8000.0 in 2023, then surged by 900.0% to $80000.0 in 2024, then slumped by 77.5% to $18000.0 in 2025.
• According to Business Quant data, Capital Expenditures over the past three periods registered $18000.0, -$876000.0, and $902000.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.